Modern Medicine News

FDA approval of retinal dystrophy drug launches era of ocular gene therapyVoretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) was approved in December 2017 for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Clinical trial results and patient selection issues for this gene therapy are discussed.
Addressing the main cause of physician burnout
Addressing the main cause of physician burnoutThere is little argument that the EHR, and especially meaningful use of the EHR, are the main drivers of physician burnout and decreased productivity.
How advances in phaco benefit glaucoma surgeryAdvances in phacoemulsification are creating new opportunities for glaucoma surgery, especially in developing countries, according to Alan S. Crandall, MD.
Ophthalmologists called upon to help impaired colleaguesOphthalmologists must take an active role in preventing impaired colleagues from hurting patients, according to Terri Pickering, MD.
Glaucoma 'renaissance' builds from expanding surgical optionsUntil now, surgery has been considered a second-line treatment after medication and lasers because of the risks associated with trabeculectomy and tube shunts. Now ophthalmologists can draw from a larger surgical tool chest, explains Iqbal Ike K. Ahmed, MD.
The true power of medicine
The true power of medicineThe best physicians heal their patients, but in turn, heal themselves and face the depths of human vulnerability and suffering, pursuing a meaning much greater than themselves.
Virtual reality on the horizon for treatment of glaucomaOne laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.
What advent of MIGS means for earlier glaucoma interventionIn addition to making use of MIGS, interventional glaucoma might utilize other novel drainage devices and sustained drug-delivery devices and be combined with cataract surgery. This approach is more proactive, aims at lower IOP, lowers risk and addresses adherence, said Iqbal Ike K. Ahmed, MD.
Shaffer Prize report goes down one path, but leads to anotherResearch aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.
Impact of rapid treatment for pediatric status epilepticus (VIDEO)For Contemporary Pediatrics, Dr Bobby Lazzara discusses a multicenter observational study published in JAMA Neurology that looked at time to treatment in children with refractory convulsive status epilepticus and the impact on mortality.